ClinicalTrials.gg
RecruitingNCT06103370Updated Nov 17, 2026

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

An interventional study of Peer-educator-based network in HIV Infections, Substance Use Disorders and Addiction, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in HIV Infections by Johns Hopkins University — 2 open to participants now, 3 under way, none of them phase 3. HIV Infections · Johns Hopkins University.

Planned enrollment
10th of 26
360 · median 193
Started
2025
the only one that year
No phase
16 of 32
1 open now
Registered
32nd of 32
by date

Among the 32 studies in HIV Infections by Johns Hopkins University, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2025, is one of 16 with no phase, and was the 32nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 32 studies in HIV Infections by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in HIV Infections by Johns Hopkins University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for HIV testing and linkage to HIV prevention and treatment services in Maryland. Study aims are to determine the effectiveness of a social network driven intervention to increase:

  • HIV testing (primary);
  • PrEP knowledge;
  • Uptake of HIV services and pre-exposure prophylaxis (PrEP);
  • Uptake of medication for opioid use disorder (MOUD) initiation.

Eligible participants who access syringe service programs (SSPs) serving two counties in Maryland and their risk network members (NMs) will be recruited using an established network inventory and coupon recruitment method. When an index successfully recruits NMs, the index-NM cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. Index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their NMs. Index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. All participants (indexes and NMs) will complete study assessments at baseline and at 3 and 9 months. We will compare the peer-educator intervention group and the equal-attention control group on rates of HIV testing, knowledge of PrEP options and resources, and rates of initiation of HIV treatment, PrEP, and MOUD treatment since the previous assessment (past 3 or 6 months).

03

Conditions studied

  • HIV Infections
  • Substance Use Disorders
  • Addiction
  • Opioid Use
  • Drug Use
  • Intravenous Drug Usage

Keywords

  • Injection Drug Use
  • HIV Prevention
  • Social Networks
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for index participants:

  • Aged 18 or older
  • Self-reported injection drug use in the prior month
  • Accessed services at the SSP in the prior 3 months
  • Willing to undergo training and attend weekly booster group sessions
  • Able to recruit at least 1 drug use Network Member (NM) into study
  • Willing to talk with peers about PWID topics such as prevention and care
  • Not previously enrolled in the study as index or NM
  • English-speaking

Inclusion criteria for network member participants:

  • Aged 18 or older
  • Self-reported injection drug use in the prior month
  • Have a valid coupon or able to recall the 3-digit ID number
  • Not previously enrolled in the study as index or NM
  • English-speaking

Exclusion criteria:

  • Individuals lacking the capacity to consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Peer-educator-based network intervention

    Indexes randomized to the intervention arm will complete a training program that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their network members (NMs).

    Behavioral: Peer-educator-based network

  • No intervention
    Equal-attention control

    This group will receive training sessions that will be focused on the opioid overdose epidemic and will not include any training to serve as a peer educator.

Interventions

  • BehavioralPeer-educator-based network

    The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.

06

What researchers measure

Primary outcomes

  1. Proportion of HIV testing for Network Members

    Proportion of Network Members (both study arms) who report that they conducted HIV testing since the previous study assessment (i.e., in the prior 3 or 6 months).

    Time frame: 3 months, 9-months

Secondary outcomes

  1. Proportion of HIV testing for Index and Network Members

    Proportion of Index and Network Members (both study arms) who report testing since the previous study assessment (i.e., in the prior 3 or 6 months).

    Time frame: 3- and 9-month follow-up

  2. Proportion of HIV testing for Index Members

    Proportion of Index Members (both study arms) who report testing since the previous study assessment (i.e., in the prior 3 or 6 months).

    Time frame: 3- and 9-month follow-up

  3. Proportion of HIV negative participants who have used PrEP

    Proportion of HIV-negative participants who have used PrEP (yes/no) since the previous study assessment (i.e., in the prior 3 or 6 months) among Network Members.

    Time frame: 3- and 9-month follow-up

  4. Change in Knowledge of PrEP options

    Knowledge of PrEP options and resources measured by questionnaire at 3 and 9 months among Network Members.

    Time frame: 3- and 9-month follow-up

  5. Proportion of participants using anti-retroviral therapy (ART)

    Proportion of participants living with HIV who reported they are currently using anti-retroviral therapy (ART), (yes/no) at the 3- or 9-month follow-up among Network Members.

    Time frame: 3- and 9-month follow-up

  6. Proportion of participants who have used Medication for opioid use disorder (MOUD) uptake

    Proportion of participants who report that they have used MOUD (yes/no) since the previous study assessment (i.e., in the prior 3 or 6 months) among Network Members.

    Time frame: 3- and 9-month follow-up

07

Study locations

1 of 2 sites recruiting
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Not yet recruiting
  • Frederick County Health Department, Street Safe Program
    Frederick, Maryland 21701, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2028, 37 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 37 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 26, 2023
StartActual
Oct 28, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06103370
Collaborators
National Institute on Drug Abuse (NIDA), Maryland Department of Health and Mental Hygiene
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Oct 28, 2025
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Oluwaseun Falade-Nwulia, MBBS, MPH
Contact
ofalade1@jhmi.edu
410-550-6234
Gregory Lucas, MD
Contact
glucas@jhmi.edu
410-614-0560
Oluwaseun Falade-Nwulia, MBBS, MPH
principal investigator · Johns Hopkins School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion